ANAB$66.9
Chart
Performance
Key Stats
AI ANAB Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralAnaptysBio (ANAB) shows mixed signals. While its long-term performance has been volatile, recent quarterly performance shows some positive signs. However, significant losses and a lack of profitability are concerns. The stock's technical indicators are mixed, suggesting a neutral stance.
Thematic
AnaptysBio operates in the biotechnology sector, focusing on immunology therapeutics. The company's pipeline of antibody programs targeting autoimmune and inflammatory diseases presents thematic growth potential, aligned with increasing demand for novel treatments in this area.
Fundamental
AnaptysBio is currently unprofitable, with significant net losses reported across multiple periods. While revenue has shown growth, it has not yet translated into profitability. The company's cash position is a key consideration for funding ongoing development.
Technical
The stock price has experienced significant volatility, with a notable decline over the past year (-27.42%). Current short-term technical indicators suggest a lack of strong momentum, with most moving averages indicating selling pressure.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 80 |
| Immunology Market Growth | 75 |
| Competition | 50 |
| Regulatory Landscape | 60 |
| Partnerships & Collaborations | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 70 |
| Balance Sheet Health | 60 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Volume Confirmation | 40 |
| Support & Resistance | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprise Trend
The company has exceeded earnings per share (EPS) estimates in the last two reported quarters (Q1 2025 and Q4 2024), indicating a trend of better-than-expected profitability.
Improving Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio has decreased significantly from 46.1 in 2023 to 9.0 in Q4 2024, suggesting the company's revenue is becoming more attractively valued relative to its market capitalization.
Bearish Points (7)
Consistent Negative Earnings
The company has consistently reported negative EPS (TTM: -4.76) and net income (TTM: -93.964 million), indicating ongoing profitability challenges.
Negative Price-to-Earnings Ratio
The Price-to-Earnings (P/E) ratio is not applicable (null) for TTM and negative for annual periods, reflecting a lack of profitability which makes traditional P/E valuation metrics unusable.
Calendar
August 2025
4
Next Earnings Date
H: $-1.26
A: $-1.58
L: $-1.81
H: 23.90M
A: 11.68M
0Profile
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Seasonals
Price Target
49.00 USD
The 39 analysts offering 1 year price forecasts for ANAB have a max estimate of 90.00 and a min estimate of 18.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Leading competitor in atopic dermatitis and asthma with Dupixent (dupilumab), a key biologic that addresses similar inflammatory indications as AnaptysBio's pipeline.
Weight: 93
Major player in immunology with a strong portfolio including Skyrizi (risankizumab) and Rinvoq (upadacitinib) for various inflammatory diseases like IBD, psoriasis, and atopic dermatitis.
Weight: 92
Significant immunology pipeline with assets like lebrikizumab for atopic dermatitis and Omvoh (mirikizumab) for IBD, directly overlapping with AnaptysBio's therapeutic focus.
Weight: 90
Partner with Regeneron on Dupixent; possesses an extensive immunology research and development presence, including other inflammatory disease assets.